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Abstract
Background: In celiac disease gluten, the disease-inducing toxic component in wheat, induces the secretion of
autoantibodies which are targeted against transglutaminase 2 (TG2). These autoantibodies are produced in the small-
intestinal mucosa, where they can be found deposited extracellularly below the epithelial basement membrane and
around mucosal blood vessels. In addition, during gluten consumption these autoantibodies can also be detected in
patients' serum but disappear from the circulation on a gluten-free diet. Interestingly, after adoption of a gluten-free diet
the serum autoantibodies disappear from the circulation more rapidly than the small-intestinal mucosal autoantibody
deposits. The toxicity of gluten and the secretion of the disease-specific autoantibodies have been widely studied in organ
culture of small-intestinal biopsy samples, but results hitherto have been contradictory. Since the mucosal autoantibodies
disappear slowly after a gluten-free diet, our aim was to establish whether autoantibody secretion to organ culture
supernatants in treated celiac disease patient biopsies is related to the duration of the diet and further to the pre-
existence of mucosal TG2-specific IgA deposits in the cultured biopsy samples.
Results: In the organ culture system conducted with biopsies derived from treated celiac disease patients, gliadin
induced secretion of autoantibodies to culture supernatants, reduced epithelial cell height and increased the density of
lamina proprial CD25+ cells. However, these changes could be demonstrated only in biopsies from short-term treated
celiac disease patients, where the small-intestinal mucosal TG2-specific IgA autoantibody deposits were still present.
Furthermore, in these biopsies autoantibody secretion could be stimulated fully only after a 48-hour gliadin challenge.
Conclusion: Our results show that studies focusing on the toxic effects of gliadin in the organ culture system should be
carried out with biopsy samples from short-term treated celiac disease patients who are likely still to have mucosal IgA
deposits present. In addition to providing an explanation for the discrepancies in previous publications, the present study
also enables further validation of the organ culture method.
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Celiac disease is a gluten-induced autoimmune disease of
the small intestine characterized by small-bowel mucosal
villous atrophy with crypt hyperplasia and a profound
inflammation in the mucosa. In addition to causing dam-
age to the mucosa in genetically susceptible individuals,
gluten also provokes the production of autoantibodies
typically found in the sera of untreated celiac disease
patients. These autoantibodies recognize exclusively
endomysial antigens now identified as transglutaminase 2
(TG2). The autoantibodies are produced locally in the
mucosa [1,2], and besides being detectable in patient sera,
they are also deposited extracellularly in vivo in the
mucosa [3-7]. Furthermore, recent findings suggest that
these TG2-targeted mucosal IgA-autoantibody deposits
are already present in the early phases of the disease proc-
ess prior to manifest mucosal lesion [4,5] and before
autoantibodies appear in the serum [3-6]. After adoption
of a gluten-free diet, serum autoantibodies disappear and
the small-bowel mucosa heals usually within one year [8].
At the time the autoantibodies have disappeared from the
circulation, there may still be residual autoantibody
deposits present in the small-intestinal mucosa which will
also in due course disappear on a strict gluten-free diet
[4,6].
For over twenty years the human small-intestinal organ
culture method has been widely used in detecting the
toxic effects of wheat gliadin in celiac disease in vitro [1,9-
15]. In earlier studies the toxicity of gliadin has commonly
been demonstrated by an increased density of lamina pro-
prial lymphocytes [11-13] and reduced epithelial cell
height (ECH) [14,16] in cultured biopsy samples from
untreated and treated celiac disease patients. However,
when measuring endomysial autoantibody (EmA) secre-
tion to culture supernatants from biopsies from treated
celiac patients, the results have been contradictory.
Picarelli and associates [1] showed that in biopsies
derived from treated celiac disease patients gliadin
induces secretion of EmA to culture supernatants. In con-
trast, some studies report that the secretion of EmA can
only be achieved in half of [14,17] or even no [18] exper-
iments carried out with treated celiac patient biopsies.
And even further, it has been suggested that EmA secretion
to the organ culture system is totally independent of glia-
din challenge [18] and histological damage [14].
Due to these discrepancies among previous studies con-
cerning autoantibody secretion to the organ culture sys-
tem, our aim was to establish in both short- and long-term
treated celiac disease patients whether the antibody secre-
tion to culture supernatants is dependent on the duration
of patients' gluten-free diet (GFD). Furthermore, since in
celiac disease the small-bowel mucosal extracellular TG2-
specific IgA deposits seem to disappear slowly after a glu-
ten-free diet [6], we hypothesized that the autoantibody
secretion to supernatants is related to the existence of
mucosal TG2-specific IgA deposits in the cultured small-
bowel biopsy samples.
Results
Celiac autoantibodies
In order to study the baseline serum autoantibody levels
of study subjects, EmA and TG2 antibody (TG2-ab) titers
were measured. All five untreated celiac disease patients
involved had positive EmA (median titer 1:500, range 5–
4000) and TG2-ab titers (median titer 58.1, range 4.7–
100) in serum. In contrast, all 20 treated celiac disease
patients and all six non-celiac controls had normal serum
autoantibody levels. Furthermore, all celiac disease
patients carried either the HLA DQ2 or the DQ8 haplo-
type. When the small-bowel biopsies from celiac disease
patients were challenged in the organ culture system with
peptic-tryptic digest of gliadin (PT-gliadin) for 48 hours,
EmA was secreted to the culture supernatants in all five
untreated but in only 11 out of the 20 treated celiac cases
(Table 1). Moreover, no antibodies were found in super-
natants from non-celiac controls (Table 1).
When autoantibody secretion to culture supernatants was
investigated in relation to the duration of the gluten-free
diet, EmA was detected in supernatants after PT-gliadin
challenge in 10 out of 12 short-term (GFD 1–3 years) and
in 1 out of 8 long-term (GFD 4–20 years) treated patient
biopsy samples (Table 2, Table 3). Since the duration of
the gluten-free diet was insufficient to explain EmA secre-
tion completely, we tested whether EmA presence in the
culture supernatants was dependent on pre-existing small-
Table 1: Endomysial antibodies (EmA) in organ culture supernatants after 48 hours' in vitro PT-gliadin challenge in untreated and 
treated celiac disease patients and non-celiac controls.
EmA after 48 h in vitro PT-gliadin challenge
Positive Negative
Untreated celiac disease (n = 5) 100%
Treated celiac disease (n = 20) 55% 45%
Non-celiac control (n = 6) 100%Page 2 of 8
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treated celiac patients were divided into two groups based
on the presence or absence of mucosal IgA autoantibody
deposits (Figure 1), it was found that only biopsies
derived from patients having positive autoantibody
deposits were able to secrete EmA to the culture superna-
tants (Table 2, Table 3). In some treated celiac cases evinc-
ing mucosal IgA deposits, EmA was already secreted to the
supernatant spontaneously without PT-gliadin stimula-
tion, but both EmA and TG2 antibody titers increased sig-
nificantly after 48 hours' culture with PT-gliadin (Table
2). Although the autoantibody titers increased in culture
supernatants after PT-gliadin challenge, there was no sig-
nificant change in the intensity of mucosal IgA deposits in
Table 2: Antiendomysial (EmA) and transglutaminase-2 antibody (TG2-ab) secretion to organ culture supernatants after in vitro PT-
gliadin challenge. Organ culture of treated celiac disease patient biopsy samples (n = 11) who had small-bowel mucosal IgA deposits. 
Small-intestinal biopsy samples were cultured either with medium only or with PT-gliadin for 24 or 48 hours. EmA titers were graded 
according to intensity of staining as follows: negative (neg), weak positive (+) and strong positive (++, +++ or ++++).
EmA TG2-ab (U)
Patient GFD years Medium 24 
h
PT-
gliadin24 h
PT-gliadin 
48 h
Medium 24 
h
PT-gliadin 
24 h
PT-gliadin 
48 h
1 1 ++ +++ ++++ 11.0 17.1 37.8
2 1 ++ ++ +++ 7.3 11.8 30.3
3 1 ++ ++ +++ 16.0 6.3 26.6
4 1 + ++ +++ 12.4 13.4 9.5
5 1 ++ neg ++ 17.2 7.4 22.9
6 1 neg ++ ++ 6.5 13.1 19.9
7 1 neg neg + 7.6 5.9 24.5
8 2 neg + ++ 7.8 5.3 14.8
9 3 + ++ ++++ 21.0 10.3 30.9
10 3 neg ++ ++ 4.9 7.0 nd
11 4 ++ ++ nd 24.5 11.9 nd
Median + ++ +++* Median 11.0 10.3 24.5†
nd = not determined
GFD = gluten-free diet
* P < 0.01; † P = 0.011 compared to medium only 24 hours and PT-gliadin 24 hours.
Table 3: Antiendomysial (EmA) and transglutaminase-2 antibody (TG2-ab) secretion to organ culture supernatants after in vitro PT-
gliadin challenge. Organ culture of treated celiac disease patient biopsy samples (n = 9) who had no small-bowel mucosal IgA deposits. 
Small-intestinal biopsy samples were cultured either with medium only or with PT-gliadin for 24 or 48 hours. EmA titers were graded 
according to intensity of staining as follows: negative (neg), weak positive (+) and strong positive (++, +++ or ++++).
EmA TG2-ab (U)
Patient GFD years Medium 24 
h
PT-gliadin 
24 h
PT-gliadin 
48 h
Medium 24 
h
PT-gliadin 
24 h
PT-gliadin 
48 h
12 1 neg neg neg 2.0 4.8 13.3
13 2 neg neg neg 8.8 6.9 4.4
14 4 neg neg neg 2.2 6.2 10.3
15 4 neg neg neg 2.5 1.7 2.6
16 6 neg neg neg 8.1 7.7 12.4
17 7 neg neg neg 2.4 3.7 1.9
18 8 neg neg neg 2.5 1.3 1.7
19 14 neg neg neg 0.9 2.9 0.7
20 20 neg neg neg 11.6 2.5 11.6
Median neg neg neg Median 2.5 3.7 4.4*
GFD = gluten-free diet
* P > 0.05 compared to medium only 24 hours and PT-gliadin 24 hoursPage 3 of 8
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shown).
Determination of ECH and the number of CD25+ 
lymphocytes
In further demonstrating the toxic effects of gliadin, ECH
and the number of lamina proprial CD25+ cells were calcu-
lated in cultured biopsy samples. In summary, it was
found that these parameters were also dependent on the
presence of mucosal IgA deposits. The ECH decreased and
the density of CD25+ cells increased significantly only in
the treated celiac disease patient biopsies with pre-existing
IgA deposits (Figure 2 and 3).
Discussion
The results presented here show that gliadin toxicity, as
measured by autoantibody secretion, decrease in ECH and
increase in the density of lamina proprial CD25+ cells, can
be demonstrated in the treated celiac disease patient
organ culture system only if small-intestinal mucosal
TG2-specific IgA autoantibody deposits are still present in
the cultured biopsy samples. Patients with persisting
mucosal autoantibody deposits, normal small-bowel
mucosal villous structure and negative serum autoanti-
body levels are usually those who have been on a gluten-
free diet for a short period of time.
Our results explain the discrepancies reported in previous
papers on EmA secretion in biopsies derived from treated
celiac disease patients. Vogelsang and colleagues [18]
Small-bowel mucosal transglutaminase 2 (TG2, red)-specific IgA deposits (green) after 24 hours' organ cultureFigure 1
Small-bowel mucosal transglutaminase 2 (TG2, red)-specific IgA deposits (green) after 24 hours' organ cul-
ture. A) Positive staining (arrow) in the mucosal villous of a short-term treated celiac disease patient (gluten-free diet for 
three years). B) Negative IgA deposits (arrow) in the small-bowel mucosa of long-term treated celiac disease patient (gluten-
free diet for eight years). Co-localization of IgA deposits with TG2 is shown in yellow. Magnification 40×.
Enterocyte cell height (ECH) after organ cultureFigure 2
Enterocyte cell height (ECH) after organ culture. 
Biopsy samples of treated celiac disease patients with and 
without mucosal IgA deposits and non-celiac control 
patients. Biopsies were cultured with medium only or with 
PT-gliadin for 24 hours. The median values (horizontal line) 
and P values are calculated for each group showing a statisti-
cally significant decrease in ECH only in those treated celiac 
disease cases who had small-bowel mucosal IgA deposits in 
the cultured biopsy samples.Page 4 of 8
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lenge was achieved in only 2 out of 18 (11%) biopsy sam-
ples derived from celiac disease patients on a strict gluten-
free diet with normal mucosal villous morphology. In
contrast, biopsies from 60% of patients with dietary
lapses and 92% of untreated celiacs with ongoing
mucosal inflammation responded to the challenge in
respect of EmA secretion. Similar results have been
obtained by Biagi and associates [14] in a small-scale
study involving only seven treated celiac disease patients.
EmA secretion to the culture supernatant could not be
stimulated after a 24-hour gliadin administration in any
of the long-term (8–30 years) treated celiac patients with
normal mucosal architecture. Samples responding to the
gliadin insult were derived from patients still evincing
mucosal damage despite a gluten-free diet. In the above-
mentioned studies the treated patients unable to react to
gliadin as measured by EmA secretion were well and long-
term treated and may be hypothesized not to have small-
bowel IgA autoantibody deposits. This absence of
mucosal deposits could thus explain the discrepancy in
results. Furthermore, it has been shown that 24 hours of
gliadin treatment might not be a sufficient time to induce
EmA secretion, as shown by Picarelli and colleagues [19]
who demonstrated that a 48-hour culture period in the
presence of gliadin is needed to achieve EmA secretion in
all treated celiac disease patient samples, this also being in
agreement with the results presented in the current study
(Table 2).
It remains to be elucidated how a gliadin challenge leads
to EmA secretion in the organ culture system. Basically
there are two different possibilities. Firstly, EmA could be
actively secreted by plasma cells in the biopsy specimen
[1]. The inability of long-term treated patient biopsy sam-
ples to secrete autoantibodies to the supernatant could be
explained by the overall absence of plasma cells and
helper T cells as well as the failure of memory B cells to
become activated within the timeframe of the organ cul-
ture [17,18]. Secondly, the secretion of EmA to the culture
supernatant might simply be due to detachment of the
autoantibodies from the tissue deposits and their release
into the supernatant. However, we observed no decrease
in the intensity of the mucosal autoantibody deposits
after the organ culture. We did nevertheless see changes in
ECH and the density of CD25+ cells, which speaks in
favor of an active gliadin-induced process, this supporting
the first proposition.
Conclusion
Our results indicate that when studying the toxic effects of
gliadin in an organ culture setting, biopsy samples from
short-term treated celiac disease patients who are likely
still to have mucosal TG2-specific IgA deposits should be
used. Altogether, the current study provides a platform for
further validation of the organ culture method.
Methods
Patients
Small-bowel mucosal biopsies were taken from 20 treated
patients suffering from celiac disease (median age 54
years, range 23–73 years, females 80%), five untreated
celiac patients (median age 48 years, range 43–71 years,
females 100%) and six non-celiac control subjects suffer-
ing from dyspepsia (median age 53 years, range 24–70
years, females 50%). In all celiac patients the diagnosis
was initially based on the European Society of Pediatric
Gastroenterology and Nutrition criteria [20], meaning
that they all had small-bowel mucosal villous atrophy
with crypt hyperplasia in the duodenum while consuming
gluten. All treated celiac patients involved in the current
study had been on a strict gluten-free diet for at least one
year (median duration of GFD three years, range 1–20
years), and all, as well as the non-celiac controls, showed
normal small-bowel mucosal architecture. In contrast, all
the untreated patients evinced subtotal villous atrophy
with crypt hyperplasia in the small-bowel mucosa. The
study protocol was accepted by the Ethical Committee of
Tampere University Hospital and written informed con-
sent was obtained from all patients and controls.
The total number of mucosal lamina proprial CD25-positive -cellsFigure 3
The total number of mucosal lamina proprial CD25-
positive T-cells. Cultured biopsy samples from treated 
celiac disease patients with and without mucosal IgA deposits 
and non-celiac control patients. Biopsies were cultured 
either with medium only or with PT-gliadin for 24 hours. The 
median values (horizontal line) and P values are calculated for 
each group showing a statistically significant increase in 
CD25+ cells only in those treated celiac disease cases who 
had small-bowel mucosal IgA deposits in the cultured biopsy 
samples.Page 5 of 8
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Altogether seven small-bowel mucosal biopsy samples
were obtained from each patient during upper gastrointes-
tinal endoscopy. Two samples were immediately snap-
frozen in liquid nitrogen with optimal cutting tempera-
ture compound (OCT, Tissue-Tek, Sakura Finetek Europe,
Holland) and stored at -20°C until used. Further, two
biopsies were immediately fixed in paraffin for investiga-
tion of the baseline small-bowel mucosal morphology.
The remaining three biopsies were cultured for 24 or 48
hours at 37°C, either in the presence or absence of a pep-
tic-tryptic digest of gliadin (1 mg/ml) prepared by a stand-
ard protocol described elsewhere [15,21].
The organ culture method was implemented as originally
described by Browning and Trier [9]. Briefly, the biopsy
samples were cultured in RPMI-1640 medium (Invitro-
gen-Gibco, Paisley, Scotland, UK) containing 15 % heat-
inactivated fetal bovine serum (Invitrogen-Gibco), 100
μg/ml streptomycin (Invitrogen-Gibco), 100 U/ml peni-
cillin (Invitrogen-Gibco), 4 mM L-glutamine (Invitrogen-
Gibco), 50 μg/ml insulin (Sigma-Aldrich Co, St. Louis,
Missouri, USA) and 10 mM HEPES buffer (Invitrogen-
Gibco). Duodenal specimens were placed villi upwards
on a sterile stainless-steel grid positioned over the
medium in a central well of the organ culture dish (Fal-
con, Becton Dickinson and Co, USA). After 24 or 48
hours' incubation, culture supernatants were collected
and stored at -70°C until analysed. Free fluid was
removed from the samples, whereafter they were snap-fro-
zen with OCT and stored at -20°C until processed for
stainings.
Celiac autoantibodies
EmA was detected in patients' serum and undiluted organ
culture supernatants using an indirect immunofluores-
cence assay where human umbilical cord was used as anti-
gen [8]. A serum dilution of 1:≥5 was considered positive.
Antibody titers for organ culture supernatants were graded
according to the intensity of the staining as follows: nega-
tive (neg), weak positive (+) and strong positive (++, +++
or ++++). Samples were analyzed blindly without knowl-
edge of the patients' clinical background.
TG2-antibodies were measured by enzyme-linked immu-
nosorbent assay (ELISA, Celikey®, Phadia, Freiburg, Ger-
many), according to manufacturer's instructions, both in
serum samples (diluted 1:100) and in undiluted culture
supernatants. In serum samples a unit value (U) ≥ 5U was
considered positive. Since there is no cut-off value for
TG2-antibody in culture supernatants, the crude antibody
values are given only for comparison to EmA.
Small-bowel mucosal TG2-specific IgA deposits
The small-bowel mucosal TG2-targeted IgA deposits were
investigated before and after 24 hours of organ culture. In
earlier studies it has been shown that these mucosal IgA
deposits are specifically targeted against TG2 in the small-
bowel mucosa [3,6]. In the studies in question, autoanti-
body specificity for TG2 was demonstrated by the fact that
IgA eluted from duodenal mucosa bound intensively to
purified TG2 in ELISA and Western blot [3]. Similarly, a
human recombinant TG2 was capable of depositing
celiac-specific IgA in small-bowel sections from celiac dis-
ease patients [6]. In addition, after removal of TG2 from
the sections by a specific acid, both TG2 and IgA deposits
disappeared from the mucosa [6].
To study the mucosal IgA deposits the 5-μm-thick unfixed
cryostat sections were stained using a two-color immun-
ofluorescence method as previously described [3]. The
monoclonal primary antibody against TG2 (Clone CUB
7402, NeoMarkers, Fremont, USA, 1:200) was used fol-
lowed by the rhodamine-conjugated antimouse immu-
noglobulin antibody (Dako, A/S, Glostrup, Denmark
1:120) and the fluorescein isothiocyanate-conjugated rab-
bit antibody against human IgA (Dako, 1:40). In
untreated celiac disease a clear extracellular subepithelial
IgA deposition can be found below the basement mem-
brane along the villous and crypt epithelium and around
mucosal vessels; this is in contrast to non-celiac normal
small-bowel samples, where IgA is detected only inside
plasma and epithelial cells [4,6,22].
Determination of ECH and the number of CD25+ 
lymphocytes
ECH was measured under a light microscope (Olympus
BX60, 40× magnification) after 24 hours' organ culture
with or without PT-gliadin challenge using the analySIS
3.0 program, (Soft Imaging System GmbH, Munster, Ger-
many). Altogether 30 enterocytes from three different villi
of each specimen were analyzed and a mean ECH value
was calculated for each biopsy sample [14].
CD25-positive T cells were detected in the lamina propria
of small-bowel mucosa from biopsy samples cultured for
24 hours with or without PT-gliadin. The 5-μm-thick cry-
ostat sections were fixed in acetone and incubated with
goat normal serum (Vector Laboratories Inc., Burlingame,
USA), whereafter they were incubated with mouse mono-
clonal antibody, human anti-CD25 (Dako, 1:25) for one
hour and alexa-conjugated goat anti-mouse IgG (Invitro-
gen, 1:1000) for 30 minutes. Washes with PBS were per-
formed between each antibody. The density of small-
bowel mucosal CD25-positive T-cells in the lamina propria
was calculated and presented as number of cells in a total
area of one mm2 of lamina propria [12,13].Page 6 of 8
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Celiac disease is strongly associated with the HLA gene
region, since over 95% of celiac disease patients have
either HLA DQ2 or HLA DQ8 haplotype molecules
[23,24]. HLA-DQ typing was performed in each patient
using DELFIA® Celiac Disease Hybridization Assay (Perk-
inElmer Life and Analytic Sciences, Wallac Oy, Turku, Fin-
land).
Statistical analysis
Statistical analysis was performed using 2-tailed Wilcoxon
Signed Ranks Test or Mann-Whitney U Test, as appropri-
ate. P values lower than 0.05 were considered statistically
significant.
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